Pharmaceuticals, Biotechnology and Life Sciences
Destiny Pharma, a clinical stage biotech company focused on the development of new anti-microbial drugs, has appointed Neil Clark as Chief Executive Officer (CEO) and member of the Board of Directors, effective immediately.
Innovative UK poured almost a million pounds to a developer of cell therapies including hematopoietic cell replacement therapies, Plasticell.
Roche has announced the global launch of the anti-p504s (SP116) Rabbit Monoclonal Primary Antibody2 for prostate cancer diagnosis.
argenx has initiated a Phase II trial of ARGX-110 as a monotherapy in patients with relapsed/refractory cutaneous T-cell lymphoma (CTCL).
Roche’s randomised phase III ALEX study showed that Alecensa (alectinib) as an initial (first-line) treatment significantly reduced the risk of disease worsening or death (progression-free survival, PFS) compared to crizotinib in people with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).
Akers Biosciences, a developer of rapid health information technologies, has reported its financial results for the fiscal year ended December 31, 2016.
Johnson & Johnson’s company Codman Neuro has acquired Neuravi Limited, a company dedicated to advancing neurovascular therapies and improving clinical outcomes for acute ischemic stroke patients.
The European Medicines Agency has had expressions of interest to host the London-based regulator from 21 of the 27 countries that will form the European Union once Britain leaves, revealing rivalry from Amsterdam to Zagreb for a prized institution.
Akers Biosciences, a developer of rapid health information technologies, has begun marketing its rapid test for heparin-induced thrombocytopenia (“HIT”) to the large number of hospital facilities in Puerto Rico as an extension of the company’s strategy to accelerate U.S. sales of its flagship product.
After receiving and analyzing legally binding transaction offers from two consortia for a public tender offer for all outstanding shares, Stada’s Executive and Supervisory Board has reached the conclusion to support the bid by Bain Capital and Cinven.